Latest Ratios: P/E Ratio -1.0x · EV/EBITDA N/A · ROE -74.4%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $63M | $39M | $115M | $213M | $311M | $155M | — |
| Enterprise Value | $4M | $-19304847 | $5M | $184M | $300M | $30M | — |
| P/E Ratio → | -1.05 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 1.11 | 0.70 | 1.10 | — | — | 1.05 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -74.4% | -74.4% | -5304.4% | — | -63.6% | -75.7% | — |
| ROA | -67.2% | -67.2% | -69.9% | -136.5% | -34.7% | -38.0% | -35.2% |
| ROIC | — | — | — | — | — | -305.6% | — |
| ROCE | -78.4% | -78.4% | -81.9% | -189.9% | -37.6% | -40.1% | -38.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.04 | -1.06 | — | — | -0.85 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -174.58 | — | — | — | — |
Net cash position: cash ($59M) exceeds total debt ($549000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 10.28 | 10.28 | 10.73 | 4.64 | 2.46 | 24.79 | 12.01 |
| Quick Ratio | 10.28 | 10.28 | 10.73 | 4.64 | 2.46 | 24.79 | 12.01 |
| Cash Ratio | 9.97 | 9.97 | 10.52 | 4.10 | 2.08 | 23.81 | 11.71 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $14M | $13M | $13M | $13M | $2M | $3M |
Clinical trial execution risk
According to recent market data, OnKure trades at a price-to-book ratio of 1.08, which suggests that investors are currently valuing the company primarily on its net asset base rather than assigning significant speculative premium to the potential success of the OKI-179 clinical program.
The current valuation multiple appears to reflect a significant discount relative to peers like Tango Therapeutics, which command higher multiples despite similar clinical-stage profiles. This suggests the market may be pricing in higher execution risk or skepticism regarding the HDAC inhibitor mechanism, warranting further investigation into whether the current valuation provides an asymmetric entry point.
As reported in financial statements, OnKure's ROIC of -6.2% in 2024Q4 underscores the inherent difficulty of generating positive returns on invested capital while the company remains in a pre-revenue, high-expenditure phase of its clinical development lifecycle for the OKI-179 lead asset.
The negative return profile is typical for a biotechnology firm at this stage, where capital is consumed by clinical trials rather than deployed into revenue-generating assets. Investors should monitor whether future clinical data readouts can catalyze a shift toward value creation, as current returns are entirely dependent on the successful progression of the pipeline.
Based on recent SEC filings, the company maintains a current ratio of 13.78 as of 2026Q1, providing a robust liquidity cushion that appears sufficient to fund operations through the near-term clinical milestones for the OKI-179 program without immediate reliance on dilutive capital markets.
This high liquidity position is a direct result of the recent reverse merger, which successfully recapitalized the balance sheet. While this provides a comfortable runway, the company's reliance on external funding remains a structural reality that investors should monitor as clinical trial costs escalate.
As indicated by the company's pre-revenue status, the use of P/E or EV/EBITDA ratios is fundamentally misapplied to OnKure, as these metrics obscure the binary nature of clinical-stage biotech value which is driven by trial outcomes rather than current operational earnings or cash flow generation.
Analysts should instead focus on cash burn rates relative to clinical milestones and the probability-adjusted net present value of the lead asset. Relying on traditional valuation multiples in this context may lead to erroneous conclusions about the company's intrinsic value, as these ratios fail to capture the potential for a rapid rerating upon positive clinical data.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OKUR stock.
OnKure Therapeutics, Inc.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
OnKure Therapeutics, Inc.'s return on equity (ROE) is -74.4%. The historical average is -71.2%.
Based on historical data, OnKure Therapeutics, Inc. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.